X

Drug Profile

LU AA 24493

Alternative Names: Carbamylated EPO; Carbamylated erythropoeitin; Carbamylerythropoietin; CEPO; Lu AA24493

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Warren Pharmaceuticals
Developer Lundbeck A/S
Class Neuroprotectants; Recombinant erythropoietins
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Friedreich's ataxia; Stroke

Most Recent Events

10 Aug 2011 Discontinued - Phase-I for Stroke in European Union (IV)
10 Aug 2011 Discontinued - Phase-I for Stroke in Singapore (IV)
10 Aug 2011 Discontinued - Phase-II for Friedreich's ataxia in Austria (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com